US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

14.42

+0.02000.14%

Volume:362.38K

Turnover:5.31M

Market Cap:665.12M

PE:18.25

High:15.18

Open:14.40

Low:14.40

Close:14.40

52wk High:64.23

52wk Low:9.25

Shares:46.12M

Float Shares:28.59M

Volume Ratio:0.64

T/O Rate:1.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.7900

EPS(LYR):1.80

ROE:16.40%

ROA:3.99%

PB:2.23

PE(LYR):8.01

Loading ...

Overview Company News Filings

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Oddity Tech CFO Lindsay Drucker Mann Disposes of 39,360 Common Shares Worth $587,688.94

Oddity Tech Files Initial Beneficial Ownership Statement for Director Dave Scott Cohen

Oddity Tech CFO Lindsay Drucker Mann Disposes of 3,493 Shares for $52,423.93

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

Oddity Tech Names Ex-Morgan Stanley IM Executive David S. Cohen Independent Director, Audit Committee Member

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

Press Release: Radiopharm Theranostics Reports Business Update

ODDITY Tech Shareholders Approve All Proposals at 2026 Annual Meeting

5 Microcap Software Stocks Expected to Soar by Triple Digits as the Companies' Sales Pop

ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 1.65 Million in Common Shares

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/ODD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":14.42,"timestamp":1788285712190,"preClose":14.4,"halted":0,"volume":362376,"delay":0,"changeRate":0.0013888888888888592,"floatShares":28586000,"shares":46124600,"eps":0.79,"marketStatus":"Trading","change":0.02,"latestTime":"09-01 14:01:53 EDT","open":14.4,"high":15.175,"low":14.4,"amount":5314086.044064,"amplitude":0.053819,"askPrice":14.42,"askSize":88,"bidPrice":14.4,"bidSize":206,"shortable":3,"etf":0,"ttmEps":0.79,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":14.4,"preHourTrading":{"tag":"盘前","latestPrice":14.37,"preClose":14.4,"latestTime":"09:29 EDT","volume":572,"amount":8220.167384,"timestamp":1788269399999,"change":-0.03,"changeRate":-0.002083,"amplitude":0.011632},"postHourTrading":{"tag":"盘后","latestPrice":14.4,"preClose":14.4,"latestTime":"19:48 EDT","volume":39801,"amount":573190.071512,"timestamp":1788220083388,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.639421,"impliedVol":1.3546,"impliedVolPercentile":0.9921},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","floatShares":28586000,"roa":"3.99%","roe":"16.40%","lyrEps":1.8,"volumeRatio":0.639421,"shares":46124600,"dividePrice":0,"high":15.175,"amplitude":0.053819,"preClose":14.4,"low":14.4,"week52Low":9.2501,"pbRate":"2.23","psRate":"0.90","week52High":64.23,"institutionHeld":0,"latestPrice":14.42,"committee":0.401361,"eps":0.79,"divideRate":0,"volume":362376,"delay":0,"ttmEps":0.79,"open":14.4,"prevYearClose":40.18,"prevWeekClose":14.35,"prevMonthClose":14.4,"prevQuarterClose":15.13,"fiveDayClose":14.2,"twentyDayClose":15.31,"sixtyDayClose":9.81,"earningDate":1788883200000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODD\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"ODD","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":0,"defaultRemindTime":1788940800000,"name":null,"time":"Pre-MKt","dateTimestamp":1788926400000,"actualEps":null},{"market":"US","date":"2026-06-02","symbol":"ODD","fiscalQuarterEnding":"2026/03","expectedEps":-0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1780372800000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2026-02-25","symbol":"ODD","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771995600000,"reportTimeType":"pre","actualEps":0.1},{"market":"US","date":"2025-11-19","symbol":"ODD","fiscalQuarterEnding":"2025/09","expectedEps":0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763528400000,"reportTimeType":"post","actualEps":0.28},{"market":"US","date":"2025-08-04","symbol":"ODD","fiscalQuarterEnding":"2025/06","expectedEps":0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754280000000,"reportTimeType":"post","actualEps":0.76}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.7,"sell":0.3,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.7,"analysts":10,"updateTime":1780718400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODD","date":"2026-08-31","current":18.240506,"percent":0.120779,"low":6.104615,"twenty":18.932683,"median":26.737148,"eighty":37.364461,"high":144.174884,"avg":28.978641,"sd":16.660608,"marketCap":661887349},"quantilePoints":[{"date":"2023-07-21","current":130.121737,"twenty":124.979326,"median":126.90773,"eighty":128.836134,"marketCap":2827285100},{"date":"2023-07-28","current":127.857619,"twenty":126.192061,"median":128.560276,"eighty":129.606455,"marketCap":2778090339},{"date":"2023-08-04","current":144.174884,"twenty":128.138682,"median":130.121737,"eighty":138.668132,"marketCap":3132631890},{"date":"2023-08-11","current":59.921033,"twenty":128.138682,"median":131.59899,"eighty":138.150305,"marketCap":3096718967},{"date":"2023-08-18","current":49.805463,"twenty":52.028567,"median":129.262933,"eighty":135.506534,"marketCap":2573946329},{"date":"2023-08-25","current":45.155781,"twenty":48.598524,"median":91.807378,"eighty":132.13135,"marketCap":2333650744},{"date":"2023-09-01","current":45.716381,"twenty":47.266275,"median":50.709145,"eighty":131.711973,"marketCap":2362622552},{"date":"2023-09-08","current":40.286255,"twenty":46.134083,"median":49.805463,"eighty":131.410685,"marketCap":2081993665},{"date":"2023-09-15","current":40.648996,"twenty":43.649855,"median":48.206104,"eighty":130.121737,"marketCap":2100740129},{"date":"2023-09-22","current":30.701094,"twenty":40.692965,"median":47.574055,"eighty":129.262933,"marketCap":1586632553},{"date":"2023-09-29","current":31.151773,"twenty":36.878686,"median":46.562777,"eighty":127.857619,"marketCap":1609923614},{"date":"2023-10-06","current":28.491671,"twenty":32.503808,"median":45.749357,"eighty":123.693723,"marketCap":1472449544},{"date":"2023-10-13","current":31.976185,"twenty":32.503808,"median":44.402818,"eighty":59.921033,"marketCap":1652529215},{"date":"2023-10-20","current":29.832714,"twenty":31.459553,"median":41.803173,"eighty":57.306257,"marketCap":1541754654},{"date":"2023-10-27","current":29.832714,"twenty":31.15617,"median":40.714949,"eighty":54.667412,"marketCap":1541754654},{"date":"2023-11-03","current":29.678824,"twenty":30.355941,"median":40.467625,"eighty":50.479578,"marketCap":1533801609},{"date":"2023-11-10","current":30.298177,"twenty":30.305454,"median":36.878686,"eighty":50.003322,"marketCap":1598562121},{"date":"2023-11-17","current":37.221321,"twenty":30.355941,"median":36.411519,"eighty":49.783479,"marketCap":1963834134},{"date":"2023-11-24","current":37.016749,"twenty":30.445709,"median":37.119035,"eighty":49.462508,"marketCap":1953040715},{"date":"2023-12-01","current":36.693741,"twenty":30.5941,"median":37.016749,"eighty":48.26876,"marketCap":1935998475},{"date":"2023-12-08","current":40.591374,"twenty":30.734071,"median":37.17287,"eighty":48.041138,"marketCap":2141641505},{"date":"2023-12-15","current":46.060981,"twenty":30.923136,"median":37.910406,"eighty":47.753992,"marketCap":2430223438},{"date":"2023-12-22","current":50.712301,"twenty":31.153971,"median":38.59949,"eighty":48.041138,"marketCap":2675631695},{"date":"2023-12-29","current":50.884572,"twenty":31.160567,"median":38.868664,"eighty":49.761494,"marketCap":2684720890},{"date":"2024-01-05","current":46.7716,"twenty":31.28148,"median":39.765881,"eighty":49.183424,"marketCap":2467716366},{"date":"2024-01-12","current":46.965405,"twenty":31.46395,"median":40.526773,"eighty":48.323896,"marketCap":2477941710},{"date":"2024-01-19","current":45.899477,"twenty":31.472743,"median":40.645209,"eighty":48.306372,"marketCap":2421702318},{"date":"2024-01-26","current":45.684138,"twenty":31.580467,"median":40.703957,"eighty":48.306372,"marketCap":2410340824},{"date":"2024-02-02","current":45.156558,"twenty":31.989432,"median":42.12028,"eighty":48.252127,"marketCap":2382505165},{"date":"2024-02-09","current":48.246671,"twenty":32.113484,"median":43.346019,"eighty":48.217673,"marketCap":2545542596},{"date":"2024-02-16","current":46.125583,"twenty":32.418946,"median":44.467474,"eighty":48.217673,"marketCap":2433631886},{"date":"2024-02-23","current":42.389454,"twenty":32.503808,"median":43.451996,"eighty":48.101679,"marketCap":2236509975},{"date":"2024-03-01","current":45.414965,"twenty":32.586249,"median":43.346019,"eighty":47.880595,"marketCap":2396138958},{"date":"2024-03-08","current":42.187798,"twenty":32.646706,"median":43.451996,"eighty":47.880595,"marketCap":2469420590},{"date":"2024-03-15","current":43.718187,"twenty":32.976471,"median":43.684021,"eighty":47.798976,"marketCap":2559000375},{"date":"2024-03-22","current":43.038127,"twenty":33.910804,"median":43.451996,"eighty":47.751391,"marketCap":2519193702},{"date":"2024-03-28","current":41.755726,"twenty":34.121582,"median":43.229275,"eighty":47.682483,"marketCap":2444129691},{"date":"2024-04-05","current":35.33401,"twenty":34.429566,"median":43.074483,"eighty":47.592295,"marketCap":2068240969},{"date":"2024-04-12","current":35.168853,"twenty":35.003425,"median":42.938568,"eighty":47.491972,"marketCap":2058573635},{"date":"2024-04-19","current":32.672059,"twenty":33.859301,"median":42.736957,"eighty":47.44561,"marketCap":1912426280},{"date":"2024-04-26","current":30.816464,"twenty":32.666988,"median":42.389454,"eighty":47.239294,"marketCap":1803810931},{"date":"2024-05-03","current":32.701204,"twenty":32.521826,"median":42.280345,"eighty":47.139393,"marketCap":1914132280},{"date":"2024-05-10","current":30.051334,"twenty":32.188614,"median":42.12028,"eighty":47.109682,"marketCap":2161502316},{"date":"2024-05-17","current":34.470881,"twenty":32.029175,"median":41.880975,"eighty":47.036466,"marketCap":2479387030},{"date":"2024-05-24","current":28.991908,"twenty":31.962852,"median":41.668069,"eighty":46.979437,"marketCap":2085300972},{"date":"2024-05-31","current":28.39104,"twenty":31.618936,"median":40.692965,"eighty":46.967038,"marketCap":2042082299},{"date":"2024-06-07","current":35.032218,"twenty":31.466148,"median":40.618291,"eighty":46.952485,"marketCap":2519762369},{"date":"2024-06-14","current":31.434913,"twenty":31.466148,"median":40.526773,"eighty":46.846969,"marketCap":2261018998},{"date":"2024-06-21","current":31.17401,"twenty":31.40776,"median":40.286255,"eighty":46.77806,"marketCap":2242252995},{"date":"2024-06-28","current":31.039605,"twenty":31.15617,"median":39.116208,"eighty":46.676851,"marketCap":2232585660},{"date":"2024-07-05","current":32.549682,"twenty":31.153971,"median":38.825596,"eighty":46.51104,"marketCap":2341201009},{"date":"2024-07-12","current":33.300768,"twenty":31.165014,"median":38.233414,"eighty":46.411983,"marketCap":2395224351},{"date":"2024-07-19","current":31.719535,"twenty":31.193823,"median":37.851188,"eighty":46.379683,"marketCap":2281491001},{"date":"2024-07-26","current":32.889648,"twenty":31.177172,"median":37.124419,"eighty":46.315081,"marketCap":2365653680},{"date":"2024-08-02","current":30.43083,"twenty":31.177172,"median":37.016749,"eighty":46.269497,"marketCap":2188798320},{"date":"2024-08-09","current":24.621128,"twenty":31.077829,"median":36.878686,"eighty":46.15167,"marketCap":2152403648},{"date":"2024-08-16","current":25.909103,"twenty":30.914687,"median":36.319047,"eighty":46.132383,"marketCap":2264999665},{"date":"2024-08-23","current":24.744722,"twenty":30.826367,"median":35.664326,"eighty":46.112663,"marketCap":2163208317},{"date":"2024-08-30","current":23.938111,"twenty":30.576415,"median":35.479654,"eighty":46.043754,"marketCap":2092693640},{"date":"2024-09-06","current":21.999645,"twenty":30.415298,"median":35.251431,"eighty":45.974846,"marketCap":1923230948},{"date":"2024-09-13","current":22.858294,"twenty":30.138302,"median":35.032218,"eighty":45.974846,"marketCap":1998294959},{"date":"2024-09-20","current":23.144511,"twenty":29.832714,"median":34.577614,"eighty":45.899477,"marketCap":2023316296},{"date":"2024-09-27","current":25.837549,"twenty":29.733784,"median":34.493388,"eighty":45.749357,"marketCap":2258744331},{"date":"2024-10-04","current":26.907033,"twenty":29.206161,"median":34.203986,"eighty":45.716381,"marketCap":2352239691},{"date":"2024-10-11","current":26.632604,"twenty":28.857503,"median":34.05976,"eighty":45.700078,"marketCap":2328248903},{"date":"2024-10-18","current":26.737148,"twenty":28.675661,"median":33.782046,"eighty":45.684138,"marketCap":2337388251},{"date":"2024-10-25","current":24.829219,"twenty":28.39104,"median":33.498422,"eighty":45.587236,"marketCap":2170595150},{"date":"2024-11-01","current":24.874957,"twenty":27.774359,"median":33.138619,"eighty":45.414965,"marketCap":2174593614},{"date":"2024-11-08","current":25.903059,"twenty":26.907033,"median":32.701204,"eighty":45.328829,"marketCap":2624135294},{"date":"2024-11-15","current":22.412856,"twenty":26.554196,"median":32.64481,"eighty":45.156558,"marketCap":2270556768},{"date":"2024-11-22","current":25.688798,"twenty":26.266873,"median":32.549682,"eighty":45.155781,"marketCap":2602429343},{"date":"2024-11-29","current":26.196259,"twenty":26.231703,"median":32.526331,"eighty":45.078881,"marketCap":2653838175},{"date":"2024-12-06","current":27.019473,"twenty":26.102043,"median":32.510933,"eighty":44.930453,"marketCap":2737234726},{"date":"2024-12-13","current":27.882156,"twenty":26.129486,"median":32.397731,"eighty":44.829243,"marketCap":2824629741},{"date":"2024-12-20","current":24.673876,"twenty":26.102043,"median":32.284642,"eighty":44.80743,"marketCap":2499611678},{"date":"2024-12-27","current":24.555468,"twenty":26.074468,"median":32.122117,"eighty":44.68052,"marketCap":2487616283},{"date":"2025-01-03","current":24.036731,"twenty":26.028044,"median":31.982415,"eighty":44.572573,"marketCap":2435065032},{"date":"2025-01-10","current":24.916329,"twenty":25.91918,"median":31.969518,"eighty":44.533395,"marketCap":2524173675},{"date":"2025-01-17","current":25.299744,"twenty":25.850651,"median":31.948814,"eighty":44.510542,"marketCap":2563015904},{"date":"2025-01-24","current":24.983991,"twenty":25.688798,"median":31.719535,"eighty":44.467474,"marketCap":2531028186},{"date":"2025-01-31","current":26.906704,"twenty":25.660605,"median":31.631647,"eighty":44.252135,"marketCap":2725810541},{"date":"2025-02-07","current":24.025454,"twenty":25.660605,"median":31.600943,"eighty":44.067933,"marketCap":2433922614},{"date":"2025-02-14","current":24.245353,"twenty":25.528357,"median":31.476041,"eighty":43.718187,"marketCap":2456199775},{"date":"2025-02-21","current":24.809199,"twenty":25.393274,"median":31.447233,"eighty":43.663521,"marketCap":2513320700},{"date":"2025-02-28","current":26.194867,"twenty":25.287339,"median":31.363758,"eighty":43.611255,"marketCap":2658543217},{"date":"2025-03-07","current":24.561126,"twenty":25.149762,"median":31.267028,"eighty":43.481918,"marketCap":2492733193},{"date":"2025-03-14","current":25.259729,"twenty":25.127573,"median":31.17401,"eighty":43.282433,"marketCap":2563635122},{"date":"2025-03-21","current":23.829518,"twenty":25.089994,"median":31.105558,"eighty":43.231428,"marketCap":2418481566},{"date":"2025-03-28","current":23.620487,"twenty":25.062794,"median":30.968449,"eighty":43.177394,"marketCap":2397266815},{"date":"2025-04-04","current":20.886583,"twenty":24.97973,"median":30.909153,"eighty":43.121556,"marketCap":2119800209},{"date":"2025-04-11","current":22.872376,"twenty":24.935811,"median":30.865977,"eighty":43.052669,"marketCap":2321340339},{"date":"2025-04-17","current":23.075906,"twenty":24.876099,"median":30.80242,"eighty":42.991494,"marketCap":2341996807},{"date":"2025-04-25","current":24.341093,"twenty":24.812177,"median":30.590011,"eighty":42.947303,"marketCap":2470401876},{"date":"2025-05-02","current":33.211688,"twenty":24.800183,"median":30.612672,"eighty":42.912727,"marketCap":3531697688},{"date":"2025-05-09","current":37.275211,"twenty":24.812177,"median":30.809442,"eighty":42.852836,"marketCap":3963808661},{"date":"2025-05-16","current":33.075187,"twenty":24.823197,"median":30.881482,"eighty":42.719469,"marketCap":3517182333},{"date":"2025-05-23","current":36.009954,"twenty":24.840888,"median":30.917059,"eighty":42.57047,"marketCap":3829262479},{"date":"2025-05-30","current":37.968215,"twenty":24.859184,"median":31.004027,"eighty":42.466444,"marketCap":4037502005},{"date":"2025-06-06","current":40.472479,"twenty":24.875718,"median":31.151773,"eighty":42.376534,"marketCap":4303802953},{"date":"2025-06-13","current":38.84497,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"marketCap":4130735251},{"date":"2025-06-20","current":36.618957,"twenty":24.907308,"median":31.267028,"eighty":42.321149,"marketCap":3894023297},{"date":"2025-06-27","current":37.637463,"twenty":24.9212,"median":31.363758,"eighty":42.207431,"marketCap":4002330181},{"date":"2025-07-03","current":39.798375,"twenty":24.940682,"median":31.434913,"eighty":42.187798,"marketCap":4232119427},{"date":"2025-07-11","current":38.424967,"twenty":24.946182,"median":31.476041,"eighty":42.12028,"marketCap":4086072618},{"date":"2025-07-18","current":37.17546,"twenty":24.957184,"median":31.58513,"eighty":42.056896,"marketCap":3953201285},{"date":"2025-07-25","current":36.450956,"twenty":24.962685,"median":31.617964,"eighty":41.958776,"marketCap":3876158244},{"date":"2025-08-01","current":36.786958,"twenty":24.983991,"median":31.719535,"eighty":41.803173,"marketCap":3911888350},{"date":"2025-08-08","current":29.269388,"twenty":24.988656,"median":31.680004,"eighty":41.755726,"marketCap":3223525522},{"date":"2025-08-15","current":29.576073,"twenty":25.039696,"median":31.613107,"eighty":41.668069,"marketCap":3257301638},{"date":"2025-08-22","current":30.491058,"twenty":25.068568,"median":31.584654,"eighty":40.714949,"marketCap":3358071703},{"date":"2025-08-29","current":30.947283,"twenty":25.079845,"median":31.470545,"eighty":40.692965,"marketCap":3408317165},{"date":"2025-09-05","current":31.494754,"twenty":25.083205,"median":31.459553,"eighty":40.65779,"marketCap":3468611719},{"date":"2025-09-12","current":31.935772,"twenty":25.085195,"median":31.488146,"eighty":40.645966,"marketCap":3517182333},{"date":"2025-09-19","current":31.793835,"twenty":25.089994,"median":31.584179,"eighty":40.616226,"marketCap":3501550411},{"date":"2025-09-26","current":29.994279,"twenty":25.105422,"median":31.49222,"eighty":40.594895,"marketCap":3303359978},{"date":"2025-10-03","current":30.739447,"twenty":25.114201,"median":31.481537,"eighty":40.590201,"marketCap":3385427566},{"date":"2025-10-10","current":26.927161,"twenty":25.127573,"median":31.451808,"eighty":40.571566,"marketCap":2965569012},{"date":"2025-10-17","current":26.01968,"twenty":25.135101,"median":31.389658,"eighty":40.56278,"marketCap":2865625373},{"date":"2025-10-24","current":24.575011,"twenty":25.135101,"median":31.29655,"eighty":40.533764,"marketCap":2706519695},{"date":"2025-10-31","current":22.697464,"twenty":25.089994,"median":31.260978,"eighty":40.483338,"marketCap":2499739752},{"date":"2025-11-07","current":20.840778,"twenty":25.062794,"median":31.168388,"eighty":40.3235,"marketCap":2295257365},{"date":"2025-11-14","current":21.127625,"twenty":24.961585,"median":31.125566,"eighty":40.286255,"marketCap":2326848745},{"date":"2025-11-21","current":20.632506,"twenty":24.914074,"median":31.026394,"eighty":40.195833,"marketCap":2272856204},{"date":"2025-11-28","current":22.556538,"twenty":24.864441,"median":30.973992,"eighty":40.067661,"marketCap":2484805645},{"date":"2025-12-05","current":23.453377,"twenty":24.800183,"median":30.947283,"eighty":39.942199,"marketCap":2583600507},{"date":"2025-12-12","current":23.171811,"twenty":24.744189,"median":30.91898,"eighty":39.889726,"marketCap":2552583516},{"date":"2025-12-19","current":22.108118,"twenty":24.698354,"median":30.913106,"eighty":39.830715,"marketCap":2435408215},{"date":"2025-12-26","current":21.97255,"twenty":24.603474,"median":30.881482,"eighty":39.790815,"marketCap":2420474108},{"date":"2026-01-02","current":20.950571,"twenty":24.5566,"median":30.865977,"eighty":39.747975,"marketCap":2307893917},{"date":"2026-01-09","current":20.079803,"twenty":24.511489,"median":30.793745,"eighty":39.569474,"marketCap":2211970999},{"date":"2026-01-16","current":18.426908,"twenty":24.453976,"median":30.739447,"eighty":39.33668,"marketCap":2029889771},{"date":"2026-01-23","current":18.270483,"twenty":24.345533,"median":30.673548,"eighty":39.245507,"marketCap":2012658109},{"date":"2026-01-30","current":17.535284,"twenty":24.313015,"median":30.590011,"eighty":39.075971,"marketCap":1931669298},{"date":"2026-02-06","current":15.001193,"twenty":24.204717,"median":30.513869,"eighty":38.986908,"marketCap":1652516376},{"date":"2026-02-13","current":14.396348,"twenty":24.048695,"median":30.485989,"eighty":38.976221,"marketCap":1585887283},{"date":"2026-02-20","current":15.950173,"twenty":23.978855,"median":30.423064,"eighty":38.890175,"marketCap":1757055125},{"date":"2026-02-27","current":7.139339,"twenty":23.850132,"median":30.333914,"eighty":38.866509,"marketCap":790646086},{"date":"2026-03-06","current":7.224918,"twenty":23.762072,"median":30.274296,"eighty":38.85757,"marketCap":800123500},{"date":"2026-03-13","current":6.950028,"twenty":23.706908,"median":30.138302,"eighty":38.84707,"marketCap":769680898},{"date":"2026-03-20","current":7.187922,"twenty":23.614586,"median":30.055287,"eighty":38.79877,"marketCap":796026424},{"date":"2026-03-27","current":6.865617,"twenty":23.526973,"median":29.994279,"eighty":38.783466,"marketCap":760332712},{"date":"2026-04-02","current":6.855385,"twenty":23.427349,"median":29.832714,"eighty":38.753843,"marketCap":759199579},{"date":"2026-04-10","current":7.072813,"twenty":23.171299,"median":29.799737,"eighty":38.548868,"marketCap":783278670},{"date":"2026-04-17","current":7.668822,"twenty":23.13114,"median":29.705337,"eighty":38.419858,"marketCap":849283708},{"date":"2026-04-24","current":7.92462,"twenty":22.959771,"median":29.615359,"eighty":38.380611,"marketCap":877612050},{"date":"2026-05-01","current":7.326053,"twenty":22.880081,"median":29.470231,"eighty":38.282735,"marketCap":811323729},{"date":"2026-05-08","current":7.617663,"twenty":22.847068,"median":29.327683,"eighty":38.184209,"marketCap":843618039},{"date":"2026-05-15","current":6.415412,"twenty":22.722307,"median":29.206161,"eighty":38.041491,"marketCap":710474829},{"date":"2026-05-22","current":6.338673,"twenty":22.581017,"median":28.928656,"eighty":37.95404,"marketCap":701976327},{"date":"2026-05-29","current":6.701906,"twenty":22.463575,"median":28.85355,"eighty":37.93304,"marketCap":742202573},{"date":"2026-06-05","current":11.066918,"twenty":22.355552,"median":28.723098,"eighty":37.913591,"marketCap":570532817},{"date":"2026-06-12","current":12.045027,"twenty":22.082048,"median":28.568928,"eighty":37.870529,"marketCap":620957267},{"date":"2026-06-18","current":12.056017,"twenty":22.028863,"median":28.441356,"eighty":37.806965,"marketCap":621523834},{"date":"2026-06-26","current":14.440844,"twenty":21.88078,"median":28.164079,"eighty":37.786268,"marketCap":744468840},{"date":"2026-07-02","current":18.69397,"twenty":21.779625,"median":28.062977,"eighty":37.763464,"marketCap":963730211},{"date":"2026-07-10","current":19.045649,"twenty":21.529345,"median":27.910348,"eighty":37.653213,"marketCap":981860351},{"date":"2026-07-17","current":14.619425,"twenty":21.127625,"median":27.658443,"eighty":37.642713,"marketCap":753675212},{"date":"2026-07-24","current":13.894717,"twenty":20.840778,"median":27.290118,"eighty":37.637463,"marketCap":716314323},{"date":"2026-07-31","current":13.102906,"twenty":20.627222,"median":27.097913,"eighty":37.608063,"marketCap":675494093},{"date":"2026-08-07","current":12.096366,"twenty":20.299418,"median":26.927161,"eighty":37.545851,"marketCap":623603970},{"date":"2026-08-14","current":11.926373,"twenty":19.78552,"median":26.9103,"eighty":37.435797,"marketCap":614840304},{"date":"2026-08-21","current":11.192718,"twenty":19.351603,"median":26.903692,"eighty":37.382312,"marketCap":577018170},{"date":"2026-08-28","current":13.411578,"twenty":19.023056,"median":26.740169,"eighty":37.366561,"marketCap":691407064},{"date":"2026-08-31","current":12.838969,"twenty":18.932683,"median":26.737148,"eighty":37.364461,"marketCap":661887349}],"updateTime":1788285713619},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664855885","title":"Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855885","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855885?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:05","pubTimestamp":1788260700,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “C","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353981/0/en/unicycive-therapeutics-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UNCY","ODD","IE0009354923.USD","BK4183","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664823918","title":"Oddity Tech CFO Lindsay Drucker Mann Disposes of 39,360 Common Shares Worth $587,688.94","url":"https://stock-news.laohu8.com/highlight/detail?id=2664823918","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664823918?lang=en_us&edition=fundamental","pubTime":"2026-09-01 09:50","pubTimestamp":1788227441,"startTime":"0","endTime":"0","summary":"Oddity Tech CFO Lindsay Drucker Mann disposes of 39,360 common shares worth $587,688.94Oddity Tech CFO Lindsay Drucker Mann cut her stake to 116,135 Class A ordinary shares as of Aug. 31, 2026.Sold 39","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL8v4myW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oddity Tech CFO Lindsay Drucker Mann Disposes of 39,360 Common Shares Worth $587,688.94","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4183","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016184","title":"Oddity Tech Files Initial Beneficial Ownership Statement for Director Dave Scott Cohen","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016184","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016184?lang=en_us&edition=fundamental","pubTime":"2026-08-29 06:30","pubTimestamp":1787956254,"startTime":"0","endTime":"0","summary":"Oddity Tech files initial beneficial ownership statement for director Dave Scott CohenOddity Tech director Dave Scott Cohen reported 2,600 Class A ordinary shares held indirectly via an IRA.He also di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL4KyH2s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4183","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662035511","title":"Oddity Tech CFO Lindsay Drucker Mann Disposes of 3,493 Shares for $52,423.93","url":"https://stock-news.laohu8.com/highlight/detail?id=2662035511","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662035511?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:06","pubTimestamp":1787864773,"startTime":"0","endTime":"0","summary":"Oddity Tech CFO Lindsay Drucker Mann disposes of 3,493 shares for $52,423.93Oddity Tech CFO Lindsay Drucker Mann cut direct holdings to 104,492 Class A ordinary shares on Aug. 26, 2026.Sale of 3,493 s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL49jvXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oddity Tech CFO Lindsay Drucker Mann Disposes of 3,493 Shares for $52,423.93","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","IE0009354923.USD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732665","title":"RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732665","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732665?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:30","pubTimestamp":1787661000,"startTime":"0","endTime":"0","summary":"PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350436/0/en/renovorx-highlights-peer-reviewed-publication-of-pharmacokinetic-and-pharmacodynamic-pk-pd-data-supporting-tamp-platform-s-targeted-drug-delivery-in-locally-advanced-pancreatic-can.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","HYLG","LU0345780281.USD","IDNA","LU2089985449.USD","LU1169590202.USD","BK4588","PK","RNXT","IE00B19Z4B17.USD","BK4139","LU2931357623.SGD","GDOC","IE00B66KJ199.SGD","LU0274383776.USD","IAG","BK4585","IE0009354923.USD","BK4539","LABU","BK4181","BK4157","MEDX","BK4017","LU0345780521.USD","AEIS","BK4183","LU1169589451.USD","IE00B7SZL793.SGD","BK4023","LU0757428866.USD","ODD","IE0031619046.USD","NVIB","KBWY","LU1815336091.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662888737","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662888737","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662888737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624700,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350174/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-phase-ii-clinical-study-for-first-line-treatment-of-esophageal-squamous-cell-carcinoma-advances-to-expansion-stage.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCZ","COAL","CBTJ","BFAP","CBXY","CBOY","BETE","BITX","XBTY","EZBC","MNRS","MAXI","YBTC","BITY","BTRN","BTCL","BITI","BCCC","BITU","HCC","FBTC","XHB","SBIT","ODD","BAGY","PD","CBXO","BRRR","DFII","BPI","ARKB","CBTA","CBOJ","BTCC","BTF","HODL","BTCW","CBOA","GBTC","PFS","QBF","BFJL","BITB","CBTY","CBOO","BITO","OC","BTC","DEFI","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661626116","title":"Oddity Tech Names Ex-Morgan Stanley IM Executive David S. Cohen Independent Director, Audit Committee Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2661626116","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661626116?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:04","pubTimestamp":1787306643,"startTime":"0","endTime":"0","summary":"Oddity Tech names ex-Morgan Stanley IM executive David S. Cohen independent director, audit committee memberOddity Tech appointed David S. Cohen as an independent director, effective Aug. 20, 2026.Nam","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL1gQvrv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","LU1244550577.SGD","LU0320765646.SGD","BK4534","IE00B3S45H60.SGD","IAI","KBWB","LU0158827781.USD","LU0528227936.USD","LU0098860793.USD","LU2089284900.SGD","LU1162221912.USD","LU0106261372.USD","LU0882574139.USD","LU2357305700.SGD","LU0267386448.USD","LU1244550494.USD","LU1668664300.SGD","LU0234570918.USD","LU1732800096.USD","LU0795875086.SGD","BK4581","LU1988902786.USD","LU2347655156.SGD","BK4585","LU0210528500.USD","LU2133065610.SGD","LU1064131342.USD","LU1244550221.USD","ODD","LU0557290698.USD","LU2271345857.HKD","IE00BKVL7J92.USD","BK4516","LU0795875169.SGD","BK4588","LU0912757837.SGD","LU1732799900.SGD","LU1791710400.SGD","LU1363072403.SGD","LU2023251221.USD","LU2487616109.SGD","LU2028103732.USD","LU0106831901.USD","LU1791710582.SGD","LU1989772923.USD","IE00BZ1G4Q59.USD","BK4504","LU1720051017.SGD","LU0006306889.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660770364","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660770364","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660770364?lang=en_us&edition=fundamental","pubTime":"2026-08-20 10:53","pubTimestamp":1787194380,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  19, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/20/3348072/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-abstract-published-by-wclc-extended-follow-up-shows-continued-efficacy-improvement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBXY","BRRR","COAL","FBTC","HCC","QBF","CBXA","BAGY","BITY","BFJL","CBOO","BITX","BFAP","IBIT","YBTC","BETH","CBTA","BTCL","MAXI","DFII","CBOA","GBTC","ARKB","OC","PFS","DEFI","BETE","BTCW","BTRN","BTCC","EZBC","BTCZ","BTCI","BTC","BTF","BITB","XBTY","CBXJ","ORR","BPI","SBIT","XHB","BITI","BITO","CBTJ","CBTO","PD","ODD","HODL","BTCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687386","title":"Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687386","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687386?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:30","pubTimestamp":1786012200,"startTime":"0","endTime":"0","summary":"--  The Company advanced multiple global oncology and immunology programs. toward key clinical and regulatory milestones, with significant pipeline. --  Global Phase 1 data for zocilurtatug pelitecan  in combination. with a PD-L1 inhibitor in first-line SCLC to be presented at ESMO 2026;planned initiation of a registrational Phase 3 study later this year. --  Registrational Phase 3 DLLEVATE study evaluating zoci in second-line. plus SCLC remains on track, with enrollment expected to be completed in. the first half of 2027, supporting a potential U.S. accelerated approval. --  Global Phase 1/1b study of ZL-1503, a potential first-in-class. long-acting IL-13/IL-31R<ALPHA> bispecific antibody for the treatment of. atopic dermatitis, continues to advance, with initial first-in-human data. --  KarXT successfully launched in mainland China; encouraging early launch. trends building momentum ahead of potential NRDL inclusion. --  Total revenues of $106.3 million in the second quarter of 2026;","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4081","NETL","BK4022","BK4231","BK4548","BK4183","R","BK4585","BK4232","BK4588","EMA","BK4531","BK4080","ZLAB","BK4526","IND","LU2488822045.USD","ADC","BK4139","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657570414","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2657570414","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657570414?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:53","pubTimestamp":1785977580,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  05, 2026  (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its Phase II clinical study evaluating ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3339882/0/en/Leads-Biolabs-Opamtistomig-PD-L1-4-1BB-Bispecific-Antibody-Advances-to-Expansion-Phase-in-First-Line-Hepatocellular-Carcinoma-Following-Positive-Efficacy-Signals.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBXA","BFJL","COAL","BPI","XHB","CBOO","DFII","CBXY","BRRR","BTCC","CBOJ","CBTO","BITO","BTCW","BTCI","CBXO","SBIT","PD","BTC","BTCZ","HODL","BTCO","OC","BAGY","GBTC","BCCC","CBXJ","CBOY","CBTA","CBTY","BTCL","BITY","YBTC","BTFX","ODD","MAXI","BETH","EZBC","BETE","BITX","MNRS","DEFI","BITI","CBOA","BTRN","BFAP","BITU","BTF","HCC","BITB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656554658","title":"Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2656554658","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656554658?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:15","pubTimestamp":1785849300,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA, Aug.  04, 2026  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338423/0/en/Immix-Biopharma-to-Participate-in-the-Morgan-Stanley-24th-Annual-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","LU0971096721.USD","LU1720051108.HKD","IE00B775SV38.USD","XBI","LU0528227936.USD","KBWB","LU1988902786.USD","LU1074936037.SGD","LU1244550221.USD","XLV","LU0098860793.USD","LU2089283258.USD","BK4516","LU1244550494.USD","LU0314104364.USD","LU1989772923.USD","LU2028103732.USD","IE0009354923.USD","LU1732799900.SGD","LU0210528500.USD","LU1720051017.SGD","LU2023251221.USD","LU0795875169.SGD","LU1668664300.SGD","LU2347655156.SGD","LU1732800096.USD","IAI","LU0234570918.USD","LU0882574139.USD","BK4588","BK4127","LU0106261372.USD","BK4585","LU2133065610.SGD","BK4534","LU0267386448.USD","LU2487616109.SGD","LU0128526141.USD","LU1244550577.SGD","IE00BKVL7J92.USD","LU0390134368.USD","LU1791710400.SGD","LU0320765646.SGD","BK4183","LU1791710582.SGD","LU1548497426.USD","LABU","LU0795875086.SGD","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656134744","title":"Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2656134744","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656134744?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:43","pubTimestamp":1785728580,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  02, 2026  (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the Center for Drug Evaluation (CDE) of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337201/0/en/Leads-Biolabs-PD-L1-4-1BB-Bispecific-Antibody-IND-Application-for-Combination-Therapy-in-Metastatic-Colorectal-Cancer-Approved-Further-Strengthening-Gastrointestinal-Oncology-Franc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBOA","ARKB","CBXY","BTRN","CBXA","BTCW","CBTJ","BRRR","CRC","BTCI","ODD","YBTC","BTC","BCCC","XME","SGDM","BFJL","CBXJ","XHB","GDXJ","IDNA","BTCO","CBXO","EZBC","DEFI","OC","XBTY","BITY","CBOJ","FBTC","IND","BITO","MNRS","BTCZ","MAXI","BETH","HCC","BITI","PD","QBF","BTCL","BITU","HODL","BITX","CBTA","SIL","COAL","CDE","MSS","CBTO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368936","title":"Press Release: Radiopharm Theranostics Reports Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368936?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:00","pubTimestamp":1785495600,"startTime":"0","endTime":"0","summary":"endpoint, with 93% of patients treated with RAD 101 achieving concordance. with MRI imaging. Additionally, an interim analysis of 14 patients from. -- The Company anticipates the initiation of a Phase 3, multi-center,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","RAD.AU","BK7067","NVIB","GDOC","BK4183","IE0009354923.USD","MEDX","BK4139","HYLG","IDNA","RADX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655180389","title":"ODDITY Tech Shareholders Approve All Proposals at 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655180389","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655180389?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:55","pubTimestamp":1785444909,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. Class A ( ($ODD) ) has issued an announcement. On July 29, 2026, ODDITY Tech Ltd. held its Annual General Meeting of Shareholders ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-shareholders-approve-all-proposals-at-2026-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-shareholders-approve-all-proposals-at-2026-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","ODD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655801671","title":"5 Microcap Software Stocks Expected to Soar by Triple Digits as the Companies' Sales Pop","url":"https://stock-news.laohu8.com/highlight/detail?id=2655801671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655801671?lang=en_us&edition=fundamental","pubTime":"2026-07-30 23:48","pubTimestamp":1785426480,"startTime":"0","endTime":"0","summary":"These companies are all expected to show very rapid revenue growth through 2028These companies are all projected to increase revenue at a rapid pace through at least 2028. And analysts see very high u","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4187","BK4157","BKSY","WEAV","BK4023","XPER","BK4123","BK4603","BLND","IE0009354923.USD","BK4009","BK4183","DRNZ","LIDR","BK4539","RCAT","DSP","MNTN","BK4096","FTCI","SVCO","BK4097","RCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653798736","title":"ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653798736","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653798736?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:05","pubTimestamp":1784750700,"startTime":"0","endTime":"0","summary":"NEW YORK, July  22, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its second quarter 2026 financial results before the market open on Wednesday, Septembe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/22/3331716/0/en/ODDITY-to-Announce-Second-Quarter-2026-Financial-Results-on-September-9-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4183","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653277765","title":"Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277765","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653277765?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635200,"startTime":"0","endTime":"0","summary":"Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330413/0/en/Cadrenal-Therapeutics-Launches-Partnering-Process-as-Its-Cardiac-Acute-Critical-Care-Assets-Advance-to-Transaction-Readiness-Following-Landmark-ISTH-Data-Presentation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4211","IE00B66KJ199.SGD","IE00B19Z4B17.USD","ODD","LARK","LENZ","IE0009354923.USD","IE0031619046.USD","BK4139","BK4007","IE00B7SZL793.SGD","BK4539","BK4134","KD","HIT","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648255544","title":"Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 1.65 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648255544","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648255544?lang=en_us&edition=fundamental","pubTime":"2026-07-01 23:22","pubTimestamp":1782919331,"startTime":"0","endTime":"0","summary":"Oddity Tech CFO Lindsay Drucker Mann disposes of USD 1.65 million in common sharesOddity Tech CFO Lindsay Drucker Mann sold 109,602 Class A ordinary shares on June 30, 2026 at about USD 15.09 and USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL2zlsnf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 1.65 Million in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","IE0009354923.USD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530232","title":"Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530232","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530232?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:05","pubTimestamp":1782817500,"startTime":"0","endTime":"0","summary":"-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor -- -- FDA inspection of third-party facility did not occur during the NDA resubmission rev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/30/3319541/0/en/Unicycive-Therapeutics-Receives-Complete-Response-Letter-from-FDA-Regarding-Resubmitted-Oxylanthanum-Carbonate-OLC-New-Drug-Application-NDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4139","BK4183","LU2746668461.USD","IE00B1BXHZ80.USD","LU2237443382.USD","LU0757428866.USD","LU0149725797.USD","LU2746668974.SGD","BK4121","LU2237443465.HKD","IE0009354923.USD","LU0390134368.USD","UNCY","LU0267386448.USD","LU2237443978.SGD","LU0128526141.USD","LU2237443622.USD","LU2237443895.HKD","LU0971096721.USD","BK4006","CMC","CRL","IE00BFXG1179.USD","BK4539","LU0882574139.USD","LU1815336091.USD","LU0029874061.USD","BK4530","LU2237443549.SGD","ODD","LU1363072403.SGD","IE00BZ1G4Q59.USD","LU0170899867.USD","IE00BHPRN162.USD","BK4585","IE00BFMHRM44.USD","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645302473","title":"Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants","url":"https://stock-news.laohu8.com/highlight/detail?id=2645302473","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645302473?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129600,"startTime":"0","endTime":"0","summary":"The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen  Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315249/0/en/Praxis-Precision-Medicines-Receives-FDA-Breakthrough-Therapy-Designation-for-Elsunersen-for-the-Treatment-of-Seizures-Associated-with-SCN2A-Developmental-and-Epileptic-Encephalopat.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","IE0002141913.USD","IE00BJT1NW94.SGD","PRAX","BK4588","BK4200","IE0009354923.USD","LU0109394709.USD","BK4135","IE00BJJMRZ35.SGD","BK4183","LABU","BK4561","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4139","ASO","IE0009355771.USD","ODD","BK4585","LU0320765992.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":129,"code":"91000000","status":"200"}]}}